Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Jardiance Will Come Back as No. 1 in Japan SGLT2 Space after CKD Launch: NBI Chair
Nippon Boehringer Ingelheim’s Jardiance (empagliflozin) fell to the second spot in the Japanese SGLT2 market in 2021, but its planned label expansion into chronic kidney disease (CKD) will help it retrieve the No. 1 crown, Chairman and President Yoshiaki Aono…
To read the full story
Related Article
- Nippon Boehringer Ingelheim Logs 6.7% Sales Rise in 2021
April 19, 2022
- Jardiance, Ofev Drive Up Boehringer’s Japan Sales in 2021
April 6, 2022
- Boehringer’s Japan Pharma Sales Rise 3.1% in 2020 on Ofev, Jardiance
April 28, 2021
- Boehringer’s Japan Sales Up 5.4% in 2020 as Ofev, Jardiance Fare Well
March 25, 2021
- Yoshiaki Aono to Be Promoted to Chairman and President of Nippon BI in September
July 10, 2020
BUSINESS
- Takeda Hands CEO Baton to Kim after 12-Year Weber Era
June 24, 2026
- Regenxbio Clears Path to Resubmit Hunter Syndrome Gene Therapy
June 24, 2026
- Merck Biopharma Files Lurbinectedin for SCLC in Japan
June 24, 2026
- FRONTEO Joins Dementia Prevention Cohort Study with KIBIT AI
June 24, 2026
- Alfresa Invests in Digital Health Startup eMind
June 24, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…